Bluestein R H & Co. Has $372,000 Position in Teva Pharmaceutical Industries Limited (TEVA)

Bluestein R H & Co. held its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the first quarter, Holdings Channel reports. The fund owned 11,600 shares of the company’s stock at the end of the first quarter. Bluestein R H & Co.’s holdings in Teva Pharmaceutical Industries Limited were worth $372,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Cribstone Capital Management LLC increased its stake in shares of Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in shares of Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares during the last quarter. Financial Architects Inc increased its stake in shares of Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock valued at $143,000 after buying an additional 100 shares during the last quarter. Advisory Services Network LLC acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the first quarter valued at $163,000. Finally, Reilly Financial Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries Limited by 1,000.0% in the first quarter. Reilly Financial Advisors LLC now owns 5,500 shares of the company’s stock valued at $176,000 after buying an additional 5,000 shares during the last quarter. 56.26% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 0.29% during mid-day trading on Tuesday, reaching $31.42. 2,330,829 shares of the company were exchanged. The company’s 50-day moving average is $30.18 and its 200 day moving average is $33.11. The firm has a market capitalization of $31.92 billion, a price-to-earnings ratio of 402.82 and a beta of 0.49. Teva Pharmaceutical Industries Limited has a 12 month low of $27.59 and a 12 month high of $56.44.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, meeting the consensus estimate of $1.06. Teva Pharmaceutical Industries Limited had a net margin of 1.49% and a return on equity of 16.38%. The firm had revenue of $5.63 billion during the quarter, compared to analyst estimates of $5.69 billion. During the same quarter in the previous year, the firm earned $1.20 earnings per share. The firm’s revenue for the quarter was up 17.0% compared to the same quarter last year. Analysts predict that Teva Pharmaceutical Industries Limited will post $4.79 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 22nd. Shareholders of record on Monday, June 5th will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, June 1st. This represents a $1.36 annualized dividend and a yield of 4.34%. Teva Pharmaceutical Industries Limited’s payout ratio is 5,802.90%.

ILLEGAL ACTIVITY WARNING: “Bluestein R H & Co. Has $372,000 Position in Teva Pharmaceutical Industries Limited (TEVA)” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/2655993/bluestein-r-h-co-has-372000-position-in-teva-pharmaceutical-industries-limited-teva.html.

Several equities research analysts recently weighed in on the stock. Oppenheimer Holdings, Inc. set a $43.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research note on Thursday, April 6th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $42.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday, February 21st. Credit Suisse Group reaffirmed a “buy” rating and set a $39.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, May 17th. BidaskClub raised shares of Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 13th. Finally, Vetr raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $33.12 target price on the stock in a research note on Tuesday, May 2nd. One equities research analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and fourteen have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $43.56.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “TEVA”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.